Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ekso Bionics Holdings (EKSO) Shares Issued (2016 - 2025)

Ekso Bionics Holdings (EKSO) has disclosed Shares Issued for 11 consecutive years, with $3.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Shares Issued fell 66.85% to $3.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $3.9 million, a 57.25% decrease, with the full-year FY2025 number at $3.9 million, down 57.25% from a year prior.
  • Shares Issued was $3.0 million for Q4 2025 at Ekso Bionics Holdings, up from -$48000.0 in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $35.9 million in Q4 2021 to a low of -$4.0 million in Q2 2024.
  • A 4-year average of $5.1 million and a median of $2.2 million in 2021 define the central range for Shares Issued.
  • Peak YoY movement for Shares Issued: soared 1264.45% in 2024, then tumbled 66.85% in 2025.
  • Ekso Bionics Holdings' Shares Issued stood at $35.9 million in 2021, then crashed by 98.16% to $661000.0 in 2023, then skyrocketed by 1264.45% to $9.0 million in 2024, then tumbled by 66.85% to $3.0 million in 2025.
  • Per Business Quant, the three most recent readings for EKSO's Shares Issued are $3.0 million (Q4 2025), -$48000.0 (Q3 2025), and -$2.9 million (Q2 2025).